Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 6/20 | 0.34 |
| ▸ | CNR1 | P21554 | 5/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.30 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.30 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.30 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914556 | 0.93 | ALOX15 (0.34) | ALOX15LMNASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4916542 | 0.87 | GAA (0.38) | LMNASMN1; SMN2BACE1CNR1L3MBTL1 | |
| SCHEMBL4737186 | 0.86 | CNR1 (0.38) | SMN1; SMN2ALDH1A1MAPTCNR1 | |
| SCHEMBL4524137 | 0.83 | CNR1 (0.40) | LMNAALDH1A1BACE1CNR1ABCC9 | |
| SCHEMBL4914076 | 0.82 | CNR1 (0.36) | CNR1 | |
| SCHEMBL4912002 | 0.82 | TSHR (0.39) | LMNASMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL4906871 | 0.82 | ALDH1A1 (0.37) | ALDH1A1CNR1 | |
| SCHEMBL4733449 | 0.81 | CNR1 (0.41) | LMNAALDH1A1CNR1CA12CA2 | |
| SCHEMBL4784960 | 0.79 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1BACE1CNR1 | |
| SCHEMBL4915885 | 0.79 | CNR1 (0.34) | SMN1; SMN2ALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | BACE1, BACE2, PSEN1 | ALOX15 1842/4885LMNA 3185/4885SMN1; SMN2 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.